Pharming Group
Tracked across 3 events · 18 articles · First seen Apr 07, 2026 · Last active Sep 14, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Business
Impact: Pharming Group will participate in investor conferences to present its business and engage with investors, potentially increasing its visibility and investor interest.
Apr 07, 2026 · 6 articles
Regulatory
Impact: Pharming Group is the subject of the investigation and experienced a 22% stock drop after reporting weak Q2 results and cutting guidance. The company faces potential securities litigation and reputational damage, with its legacy product RUCONEST under competitive pressure.
Jul 31, 2026 · 6 articles
Regulatory
The U.S. United States — Food and Drug Administration approved Joenja (leniolisib), developed by Pharming Group, for children aged 4 to 11 years weighing at least 27 kg with activated phosphoinositide 3-kinase delta syndrome (APDS),…
Impact: Pharming Group is the developer of Joenja and the central beneficiary of the FDA label expansion, which broadens its U.S. market to children aged 4 to 11 and follows a prior regulatory setback. The approval supports revenue growth and reduces regulatory risk, though a further lower-dose application remains pending.
Sep 11, 2026 · 6 articles
ERGEN INTELLIGENCE
Track Pharming Group live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard